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1. SUMMARY OF THESIS 
The five studies forming this thesis deal with two closely related neurodegenerative diseases, 
progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), both of which are 
characterised by abundant tau-positive neuronal and glial filamentous inclusions and by 
shared genetic risk factors[19, 70]. Four studies focus on demonstrating neuropathological, 
biochemical and genetic differences between the classical/typical form and atypical PSP 
while the fifth study discusses issues relevant for understanding disease progression in CBD.  
 
Paper 1: In this study[64] we used a stereological tool (optical disector) for the investigation 
of the nucleus raphe interpositus containing the omnipause neurons, whose integrity is 
essential for normal saccadic eye movements. We found that the loss of the omnipause 
neurons and the degree of neurofibrillary degeneration in this nucleus is significantly greater 
in typical PSP than in the atypical variant, defined in this study by the absence of 
supranuclear gaze palsy (SGP), which is the classical eye movement sign in PSP[64].  
 
Paper 2: In the second study[55], in addition to neuropathological assessment of the cases, 
we carried out protein analysis of PSP-tau and investigated the tau gene (MAPT) haplotypes 
in clinically typical and atypical PSP cases. The atypical cases were clinically more 
heterogeneous than those used in paper 1; a minority of the cases was lacking SGP and some 
showed a Parkinson’s disease-like clinical presentation. We found that the characteristic 
‘doublet’ western blot pattern of PSP-tau, indicating that it primarily consists of 4-repeat tau 
(4R-tau) isoforms, and the PSP genetic susceptibility H1 MAPT haplotype are strongly 
associated with typical PSP. A deviation from this was recognised in atypical PSP in that the 
H1 MAPT haplotype was less frequent and that the 3-repeat tau (3R-tau) isoforms made a 
significant contribution to PSP-tau[55]. 
  
Paper 3: Two seminal studies from the Queen Square Brain Bank for Neurological Disorders, 
UCL Institute of Neurology (QSBB) provided a conceptual framework for reliably separating 
clinically classical/typical PSP (named Richardson’s syndrome - PSP-RS) from two atypical 
variants, PSP-parkinsonism (PSP-P)[77] and PSP-pure akinesia with gait freezing (PSP-
PAGF)[79]. Using these clinical categories, our third study[78] employing unbiased 
morphometry, showed marked differences in the cerebral tau-load between PSP-RS and 
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each of the two variants, PSP-P and PSP-PAGF in that these two atypical variants were 
associated with less severe and anatomically more restricted tau-burden than the clinically 
typical cases. Furthermore we could also demonstrate the pattern of the topographical 
expansion of the disease that is associated with an increase in the severity of the tau-
burden[78].  
 
Paper 4: Using unbiased quantitative neuropathological methods for establishing the 
cerebral tau-load, supplemented by western blot analysis of PSP-tau and investigation of the 
MAPT haplotypes, we also studied the clinically well-characterised PSP-corticobasal 
syndrome atypical variant (PSP-CBS)[46]. In this study, we could confirm findings of previous 
studies indicating that, compared with typical PSP, there is an increased cortical tau-burden 
in PSP-CBS. Furthermore, our study also demonstrated that, parallel with the increased 
cortical tau-burden, the basal ganglia tau-load is decreased in PSP-CBS, which explains why 
the total cerebral tau-burden (tau-load in all areas investigated) in PSP-CBS is similar to that 
can be found in PSP-RS. These findings also indicate that in PSP-CBS there is a marked shift 
of the tau-burden from the basal ganglia to neocortical areas[46].  
 
Paper 5: As the patterns of progression of the tau pathology are poorly understood in PSP or 
CBD, in this study[47] we investigated a group of ‘incidental’ (preclinical, clinically 
asymptomatic) CBD cases with ‘early’ pathological changes by using tau 
immunohistochemistry and unbiased quantitative neuropathological methods. Genetic 
analysis of the tau (MAPT) gene was also carried out. We found no mutation in the MAPT 
gene in any of the ‘incidental’ cases, one of which had the H1/H2 MAPT haplotype while the 
remainder had the H1/H1 haplotype. The overall severity of the tau pathology was found to 
be significantly less and anatomically more restricted in ‘incidental’ CBD than in control CBD 
cases with ‘end-stage’ pathology. Furthermore, we also found that the earliest disease stages 
are dominated by astroglial tau pathology (astrocytic plaques). Analysis of the distribution of 
the tau pathology also indicates that striatal connections to the dorsolateral prefrontal 
cortex and basal ganglia circuitry are the earliest neural network connections that are 
affected by CBD tau pathology.  
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The findings of the first four studies underpinned the validity of the emerging concept of 
clinically diverse PSP variants as we could identify relevant differences in the severity and 
distribution of the tau pathology between typical PSP and the atypical variants. These 
findings also imply that as in Alzheimer’s disease, the severity and topographical distribution 
of the tau pathology determine the clinical syndrome in both typical PSP and the atypical 
variants. Furthermore, in the atypical cases the H1/H1 tau haplotype was less frequent and 
a contribution by 3R-tau to PSP-tau was more common than in typical PSP. 
 
Our fifth study identified for the first time that in CBD the astrocytic tau pathology is 
prominent in the earliest stages of the disease and that the earliest neuropathological 
changes occur in the basal ganglia and the prefrontal cortex. This latter observation has 
important implications on our understanding the topographical progression of the tau 
pathology in this condition. 
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2. LIST OF ABBREVIATIONS AND ACRONYMS 
3R-tau = 3-repeat tau 
4R-tau = 4-repeat tau 
3R-tauopathy = 3-repeat tauopathy 
4R-tauopathy = 4-repeat tauopathy 
ALS/PD complex  = amyotrophic lateral sclerosis/parkinsonism complex 
A = amyloid- 
CAA = cerebral amyloid angiopathy 
CB = coiled body 
CBD = corticobasal degeneration 
CBD-bvFTD = CBD-behavioural variant frontotemporal dementia 
CBD-CBS = CBD-corticobasal syndrome 
CBD-PPA = CBD-primary progressive aphasia 
CBD-PSPS = CBD-progressive supranuclear palsy syndrome 
CBD-RS = CBD-Richardson’s syndrome   
CBS = corticobasal syndrome 
DNA = deoxyribonucleic acid 
EM = electron microscopy 
FTDP-17MAPT = frontotemporal dementia and parkinsonism linked to chromosome 17,     
    due to mutations in the MAPT gene 
MAPT gene = microtubule-associated protein tau gene 
mRNA = messenger ribonucleic acid 
NFT = neurofibrillary tangle 
NINDS = National Institute of Neurological Disorders and Stroke 
PHF = paired helical filament 
PreT = pretangle 
PSP = progressive supranuclear palsy 
PSP-AOS  = PSP-apraxia of speech 
PSP-C = PSP-cerebellar 
PSP-CBS = PSP-corticobasal syndrome 
PSP-FTD = PSP-frontotemporal dementia 
PSP-P = PSP-parkinsonism 
PSP-PAGF = PPS-pure akinesia with gait freezing 
PSP-PPA  = PSP-primary progressive aphasia 
PSP-RS = PSP-Richardson’s syndrome 
QSBB = Queen Square Brain Bank for Neurological Disorders 
SD = standard deviation 
SDS-PAGE = sodium dodecyl sulphate–polyacrylamide 
SEM = standard error of the mean 
SF = straight filament 
SGP  = supranuclear gaze palsy 
Th = neuropil thread 
UCL = University College London 
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3. BACKGROUND 
3.1 Clinical definition of progressive supranuclear palsy and corticobasal degeneration 
Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are clinically and 
pathologically heterogeneous diseases which, based on their clinical presentations, are 
classified as atypical Parkinsonian disorders. PSP and CBD are closely-related conditions as 
they share genetic risk factors and biochemical characteristics of the microtubule-associated 
protein tau, which in both diseases forms abundant filamentous inclusions in both neurones 
and glial cells[19, 62]. Both PSP and CBD were systematically described only in the 1960s, 
although it is likely that isolated cases had been reported earlier[61, 69, 70]. 
 
3.1.1 Progressive supranuclear palsy 
PSP is the most common atypical parkinsonian disorder[62]. In a large pathologically proven 
cohort from the QSBB, 63% of 103 cases, collected between 1988 and 2002 were male. The 
mean age at onset in this cohort was 66.4 years (SD: 12), the mean age at death 73.5 years 
(SD: 7.5) with a mean disease duration of 7.0 years (SD: 3.7)[77]. Using passive referral 
evaluation, the prevalence of classical PSP has been reported to be 0.1/100,000 in the UK 
while with active case ascertainment method, the crude and the age-adjusted prevalence 
was estimated to be 3.1/100,000 and 2.4/100,000, respectively[57]. 
 
The classical clinical syndrome of PSP includes postural instability, parkinsonism, 
ophthalmoplegia, which primarily affects downward gaze, pseudobulbar palsy, dysarthria, 
dystonic rigidity of the neck as well as upper trunk and mild dementia[69, 70]. The clinical 
signs reflect pathological involvement of numerous subcortical and brainstem structures 
such as those of the extrapyramidal motor systems or responsible for the supranuclear 
organisation of eye movements (see below)[19, 62].  
 
In 1990s clinical diagnostic criteria were developed, which showed good specificity for cases 
with classical clinical presentation, but relatively low sensitivity[49, 50, 76]. These have been 
recently updated and modified under the aegis of the Movement Disorder Society[35]. Based 
on clinical diagnostic probability, categories of ‘possible’, ‘probable’ and ‘definite’ PSP were 




3.1.2 Corticobasal degeneration 
CBD was first described clinically and neuropathologically under the term 
‘corticodentatonigral degeneration with neuronal achromasia’[61], which was later replaced 
by the term ‘corticobasal degeneration’ (CBD)[22]. As, in addition to CBD, a number of other 
conditions may also underlie the classical clinical presentation, the term corticobasal 
syndrome (CBS) is more appropriate for clinical diagnosis[45, 48]. 
 
CBD is a sporadic condition affecting both sexes equally. The calculated estimated incidence 
of CBD is thought to be less than 1/100,000 per year[19]. The average age at disease onset 
is ~60 years and the disease duration is between 6–10 years[62].  
 
The classical clinical presentation (CBS) is characteristically asymmetrical with clumsiness, 
stiffness or myoclonic jerks of a limb. Dystonic rigidity, difficulty of walking, akinesia and 
cortical sensory signs are also features and some patients show ‘alien limb’ sign.  
 
Consensus clinical diagnostic criteria have been established and, in addition to CBS (CBD-
CBS), CBD pathology has been shown to underlie several other clinical syndromes. These 
include a PSP-like syndrome/Richardson’s syndrome (CBD-PSPS/CBD-RS), behavioural 
variant of frontotemporal dementia (CBD-bvFTD), non-fluent/agrammatic variant of primary 
progressive aphasia (CBD-PPA) and rarely a presentation with cerebellar ataxia (CBD-
OPCA)[4, 43-45, 48], underpinning the notion that CBD is a disease of both movement and 
cognition[62, 63].  
 
3.2  Neuropathology 
3.2.1 Progressive supranuclear palsy  
In cases with classical clinical presentation, inspection of the brain reveals dilatation of the 
3rd and 4th ventricles, severe atrophy of the subthalamus, tegmentum of the midbrain and 
pons, marked pallor of the substantia nigra, reduction in size and discolouration of the globus 
pallidus and, in most cases, severe atrophy of the superior cerebellar peduncle due to loss 
of neurons in the cerebellar dentate nucleus. Mild frontal atrophy may be a feature. 
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Microscopic investigation confirms neuronal cell loss and astrogliosis in structures showing 
macroscopic abnormality, including the subthalamic nucleus, globus pallidus, substantia 
nigra, in which both the pars compacta and pars reticulata are affected by severe neuronal 
loss, other brainstem nuclei and the cerebellar dentate nucleus[15, 19, 59, 62, 70].  
 Neurofibrillary tangles (NFTs), some with features of globose tangles (Figure 1D), can be 
recognised on the haematoxylin and eosin preparations. Tau immunohistochemistry reveals 
severe accumulation of disease-associated, hyperphosphorylated tau in both neurons as 
NFTs as well as pretangles (PreT) and glial cells in the basal ganglia, brainstem structures, 
including supranuclear gaze centres, cerebellar nuclei, spinal cord and also cerebral cortex 
(Figure 1A, 1E)[62]. Tau deposition in astrocytes gives rise to tufted astrocytes, which are 
readily seen in the frontal cortex including motor cortex, and striatum (Figure 1A, 1B). The 
stellate-shaped tufted astrocytes with accumulation of filamentous tau in the cytoplasm and 
proximal astrocytic processes, are pathological hallmarks of PSP and are required for the 
neuropathological diagnosis[19, 62].  Tau deposition in oligodendroglia gives rise to coiled 
bodies (CBs), which can be numerous among others in the internal capsule, cerebral 
peduncles and cerebellar white matter[19, 62] (Figure 1C). Tau-positive neuropil threads 
(Ths) are also widespread.  
 
Electron microscopic examination of the tau filaments demonstrates ~15nm wide straight 
filaments.  
 
Pathological criteria for the diagnosis of PSP were established and validated under the 
auspices of the NINDS[49, 51] in the 1990s, although these have become outdated and an 














Figure 1   Main microscopic findings in progressive supranuclear palsy  
Tau-positive neurofibrillary tangles (arrows) (A, E), tufted astrocytes (double arrows) 
(A, B) and coiled bodies (arrowheads) (C) are characteristic in progressive 
supranuclear palsy. Panel D shows a globose neurofibrillary tangle in a neuron of the 
substantia nigra. Panels A,B,C and E tau immunohistochemistry (AT8 antibody), panel 
D haematoxylin and eosin stain. Scale bar on panel A represents 22.5m on panels A 
C, D and E and 90m on panel B. 
Precentral gyrus Caudate Internal capsule 
 





3.2.1 Corticobasal degeneration 
Gross inspection of the brain reveals cortical atrophy of the posterior frontal and parietal 
cortices, which may be asymmetrical and may show a parasagittal distribution in cases 
presenting with CBS. The atrophy may be more apparent in the anterior frontal and temporal 
regions in CBD-bvFTD or CBD-PPA[19]. There is variable dilatation of the ventricular 
system; the cerebral hemispheric white matter, including the corpus callosum may be 
reduced in bulk. Atrophy of the subthalamic nucleus, prominent in PSP, is minimal or absent 
in CBD. The pallor of the substantia nigra and locus coeruleus is severe in cases with 
advanced disease[19, 62]. 
 
In CBD microscopy reveals marked neuronal loss with astrocytosis in severely affected 
cerebral cortices where vacuolation of the neuropil in the upper cortical laminae is seen. 
Swollen (ballooned or achromatic) cortical neurons, most frequent in deeper cortical layers, 
can be observed, although their presence is not required for the diagnosis as they may be 
absent[18]. The subcortical grey nuclei show variable neuronal loss, which is mostly severe 
in the substantia nigra. Degeneration of the corticospinal tracts may occur due to 
degeneration of the motor cortex and there is myelin pallor in the cerebral white matter. 
 
Validated neuropathological diagnostic criteria of CBD emphasise the importance of tau-
positive Ths in grey and white matter of the cerebral cortex (Figure 2C, 2D), basal ganglia and 
rostral brainstem (Figure 2A-E). Tau-positive neuronal (NFTs and PreTs) and glial filamentous 
inclusions are also widespread. The presence of astrocytic plaques showing an annular 
arrangement of tau-positive processes (Figure 2B), is required for the diagnosis. They 
represent tau deposition in distal astrocytic processes and are prominent in affected cerebral 
cortices and striatum. Tau-positive CBs are also widespread in cortices and white matter[18, 
19, 45, 62]. Additional pathological features of argyrophilic grain disease or TDP-43 (TAR 
DNA-binding protein 43) immunoreactive lesions are found in excess of 40% of CBD cases[42, 
72]. 
 
Ultrastructurally the tau filaments extracted from CBD brains appear as 15nm wide straight 



















nucleus Substantia nigra 
Figure 2  Tau immunohistochemistry in corticobasal degeneration. Arrows in A and 
F point to neurofibrillary tangles and pretangles. The presence of astrocytic 
plaques is required for the neuropathological diagnosis (B). There is abundant tau 
accumulation in axons and oligodendroglial processes in the subcortical white 
matter (C). Coiled bodies are also a feature (D). The striatum is one of the most 
severely affected structures showing abundant tau deposition (E). The neuronal 
loss in the substantia nigra is severe in advanced cases. In better preserved areas 
of the substantia nigra a significant proportion of the neurons possess tau 
inclusions (F). Tau immunohistochemistry (AT8 antibody). Bar on A represents 
90m on A, C, E and F, 22,5m on B and D. Parietal w. matter = Parietal white 






Clinical heterogeneity of CBD, described above, is well-recognised and attempts have been 
made to support this with neuropathological markers[43, 44, 47].  
 
3.3 Genetics of progressive supranuclear palsy and corticobasal degeneration 
A strong genetic link between the MAPT gene and development of PSP and CBD have been 
demonstrated[5, 33, 60]. Of the two common, tau haplotypes (H1 and H2), H1 is 
overrepresented in both PSP and CBD Caucasian patients[5]. Familial PSP and CBD have been 
described, but these should be considered cases of ‘frontotemporal dementia and 
parkinsonism linked to chromosome 17’ due to mutations in the MAPT gene (FTDP-17MAPT). 
Genome-wide association (GWA) studies in both diseases have demonstrated the same, 
previously unidentified genetic risk factors[34, 65]. 
 
3.4 Tau biochemistry in progressive supranuclear palsy and corticobasal degeneration 
As in both PSP and CBD tau-positive neuronal and glial inclusions are the core 
neuropathological feature, they are classified as tauopathies. Tauopathy is an umbrella term 
used for a large group of diseases in which the presence of abundant tau inclusions is 
characteristic[23]. Due to alternative mRNA splicing of exons 2, 3 and 10 of the MAPT gene, 
located on 17q, there are six tau isoforms in the adult human brain. Based on the presence 
or absence of a fourth, 31 amino acid-long repeat region in the C-terminal, microtubule-
binding domain of the tau protein encoded by exon 10, there are three tau isoforms with 
four repeat sequences (4R-tau) and three isoforms with three repeat sequences (3R-tau). 
Current classification of the tauopathies takes into consideration the tau isoform 
composition of the inclusions. In a large group of diseases with primarily neuronal tau-
positive filamentous inclusions (NFTs), both 3R-tau and 4R-tau form the filaments (3R + 4R-
tauopathies) while in others with inclusions in both neurons and glia, the filaments are 
predominantly composed of either 4R-tau (4R-tauopathies) or 3R-tau (3R-tauopathies) 
(Figure 4).  In both PSP and CBD predominantly the 4R-tau isoforms form the filamentous 
inclusions with tau immunoblotting showing two strong bands at 68kDa and 64kDa (doublet 
pattern) with a third weak band at 72kDa[11, 68]. In contrast in 3R + 4R tauopathies such as 
Alzheimer’s disease there is a triplet pattern with three strong bands are at 68kDa, 64kDa 
and 60kDa and an additional fourth, weak band at 72kDa (Figures 3 and 4). The presence of 
different C-terminal tau fragments differentiate PSP and CBD; a ~33kDA fragment has been 
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described in PSP and a 37kDA fragment in CBD[3]. The isoform composition of the tau 



























Figure 3  Illustration of tau western blot patterns in Alzheimer’s disease (lane 1) and 
classical progressive supranuclear palsy (lane 2) 
In Alzheimer’s disease, there is a triplet electrophoretic migration pattern with three 
strong bands at 68kDa, 64kDa and 60kDa with a fourth weak band at 72kDa while in 
PSP a doublet pattern is characteristic (68kDa and 64kDa) with a third weak band at 
72kDa. While all six tau isoforms contribute to Alzheimer’s disease-tau, PSP-tau is 
mainly composed of 4R-tau (the fourth repeat region is represented by a blue square 
over yellow background. 
Previously unpublished blots performed by Tamas Revesz 
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Figure 4     Examples of tauopathies  
Tauopathies are classified on the basis of the tau isoform composition of the 
inclusions. The isoforms contributing to the bands seen on western blots are shown as 
N = N-terminal insert, 3R-tau = 3-repeat tau; 4R-tau = 4-repeat tau. ALS/PD complex = 
amyotrophic lateral sclerosis/parkinsonism complex; EM = electron microscopy; FTDP-
17 = frontotemporal dementia and parkinsonism, linked to chromosome 17; PHF = 




























































4. UNANSWERED QUESTIONS IN PSP AND CBD RESEARCH, 
RELEVANT FOR THE THESIS 
In their seminal paper Steele, Richardson and Olszewski[70] predicted that atypical PSP, 
clinically deviating from the classical presentation, could emerge. Indeed, subsequently a few 
atypical cases with PSP post-mortem findings were documented in the literature and these 
included cases lacking SGP[16, 20] or presenting with severe dementia[7, 16], CBS[6, 15, 80] 
or pure akinesia[54].  
 
Since its foundation in 1984, the QSBB has assembled a large cohort of PSP and CBD cases 
and by the mid-1990s cases with PSP pathology had been observed in which the clinical 
diagnosis of PSP was not suspected as the patients presented with an atypical syndrome, 
including a Parkinson’s disease-like clinical phenotype[36] and many did not show signs of 
SGP[15]. In 1995 a systematic neuropathological study from the QSBB made an attempt to 
differentiate clinically atypical from typical PSP, but it failed to demonstrate distinct 
qualitative differences in the neuropathology between these two clinical groups of PSP[15]. 
 
Unlike in Alzheimer’s disease, in which the patterns of progression of the neurofibrillary 
tangle pathology was successfully mapped over 25 years ago[9] and updated in 2006[8], the 
topographical spread of the tau pathology including the structures first affected by the 
disease process have remained enigmatic in both PSP and CBD.  
 
5. AIMS OF THESIS 
5.1  To show how our research group succeeded in differentiating clinically atypical PSP 
from typical PSP by using quantitative measures for mapping neuronal cell loss and tau 
pathology, by studying the biochemical profile of PSP-tau and employing genetic markers 
(papers 1-4).  
5.2 To demonstrate how studying the neuropathology of ‘incidental’ (preclinical) cases 
could increase our understanding the patterns of progression of the tau pathology in CBD 
(paper 5).  
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6.  INITIAL STUDIES AIMING TO DIFFERENTIATE TYPICAL AND 
ATYPICAL PSP (PAPERS 1 AND 2)  
In view of the failure of the first comprehensive study from the QSBB to demonstrate 
neuropathological differences between clinically typical and atypical PSP in 1995[15] and my 
interest in PSP including understanding the neuropathological basis of SGP in this disease, I 
proposed a study of the nucleus raphe interpositus in typical PSP and atypical PSP defined 
by the absence of SGP (paper 1)[64].  
 
Soon after the completion of the above study I established a successful collaboration with 
Professor Brian Anderton and his team at the Department of Neuroscience, Institute of 
Psychiatry, King’s College, London with the aim of extending the neuropathological studies 
with biochemical analysis of PSP-tau in typical and atypical PSP cases. For this I learned the 
necessary techniques and carried out a significant part of the biochemical studies, published 
in paper 2[55] with help from Professor Brian Anderton and his team. For our second study 
we also determined the tau gene haplotypes in the same cohort of typical and atypical cases. 
 
6.1 The nucleus raphe interpositus in typical and atypical PSP (paper 1) 
Revesz et al.: The nucleus raphe interpositus in the Steele-Richardson-Olszewski 
syndrome (progressive supranuclear palsy). Brain 119, 1137-1143, 1996[64] 
5.1.1  Background and research questions  
Just a few years before this study was carried out, the importance of the omnipause neurons 
in the organisation of saccadic eye movements had emerged[12]. In order to learn the 
neuroanatomy of the omnipause neurons, in 1994 I spent a week in the laboratory of 
Professor Jean Buttner-Ennever at the University of Munich, who played a pivotal role in 
clarifying the neuroanatomy and normal function of the omnipause neurons located in the 
nucleus raphe interpositus[12, 31].   
 
The premotor network responsible for saccadic eye movements are dependent on the 
normal function of two neuronal types located in the paramedian pontine reticular 
formation: a.) burst neurons, active before saccades and b.) pause neurons, active before 
and during saccades. Pause neurons include the omnipause neurons, located in the nucleus 
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raphe interpositus. They exert a tonic inhibition on the burst neurons, but pause before eye 
movements. The nucleus raphe interpositus with the omnipause neurons is located in the 
lower pons, just ventral to the medial longitudinal fascicle and dorsal to the gigantocellular 
nucleus. The rootlets of the of the 6th nerve represent the lateral border of the nucleus raphe 
interpositus (Figure 5). The cell soma of the glycinergic omnipause neurons is fusiform in 
shape and they possess well-developed horizontally oriented dendrites[12] (Figure 6). 
 
In the study to be discussed here, we wished to investigate 1.) whether the nucleus raphe 
interpositus is affected in PSP and if yes 2.) whether such an involvement is different in 
atypical PSP without SGP compared with typical PSP.  
 
6.1.2  Cases studied, methods used and the main findings of paper 1 
We investigated 8 typical PSP cases with SGP, 5 atypical cases without SGP and 6 
neurologically normal controls. The mean age at onset and mean disease duration are shown 
in Table 1. Patients without SGP were older than those with SGP (P=0.001, Student’s t test), 








Table 1   Mean age at onset and disease duration in typical PSP with SGP and 
atypical PSP without SPG 
Patient group  Mean age at onset 
years (SD, range) 
Mean disease duration  
      years (SD, range) 
PSP with SGP  67.3 (5.4; 57-74)                5.9 (2.6; 2-10) 
PSP without SGP  81.4 (5.8; 75-88)                6.6 (2.5; 4-9) 
Normal controls 78.8 (5.3; 72-85)                        N/A 
N/A = Not applicable; PSP = progressive supranuclear palsy; SD = Standard 
deviation; SGP = supranuclear gaze palsy 
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In this study we determined the neuronal cell density (n/mm3) of the omnipause neurons 
using an unbiased stereological method based on the principle of the optical disector[27]. 
NFT densities in the nucleus raphe interpositus were also determined. The extent of tissue 
shrinkage of the pontine tegmentum, containing the nucleus raphe interpositus, was 
estimated by calculating a ratio from measurements of the heights of the pontine 
tegmentum and base and these were used for calculating a ‘correction factor’ for each 
disease group. 
 
Neuronal cell (ND/mm3) and NFT densities (NFT/mm2) are shown in Table 2. Neuronal cell 
density was significantly lower in typical PSP than in normal controls irrespective of whether 
tissue shrinkage was taken into consideration (P=0.001, Student’s t test) or not (P=0.014, 
Student’s t test). Having adjusted for tissue shrinkage, a difference in neuronal cell density 
was also apparent between the typical and atypical PSP cases (P = 0.016, Student’s t test). 
Many of the omnipause neurons contained NFTs (Figure 5) and these were significantly more 
frequent in the typical PSP cases than in atypical PSP without SGP (P=0.011, Mann-Whitney 
U test). Furthermore, there was a moderate negative correlation between neuronal cell and 
NFT densities (Pearson’s r =-0.5647; P=0.04).  
 
 
Table 2  Densities of the omnipause neurons and neurofibrillary tangles 
 Patient groups 
Data of 
morphometry 
PSP with SGP  
(typical PSP) 


























ADJ = adjusted; ND = neuronal cell density; NFT = neurofibrillary tangle; SD = 






   
Figure 5 The nucleus raphe interpositus containing the omnipause 
neurons is located in the paramedian tegmentum of the caudal pons  
F lo m = medial longitudinal fascicle, N VI = 6
th
 nerve nucleus, Gc = gigantocellular 
nucleus, Le m = medial lemnisc, VI = rootlets of the 6
th
 nerve.  
A: Olszewski and Baxter: Cytoarchitecture of the Human Brain Stem, 2
nd
 ed. 
Karger, Basel, 1982. B: Luxol fast blue cresyl violet.  
 
Reproduced from Revesz et al. Brain 119:1137-43, 1996 with permission from 




Figure 6   Omnipause neurons in the nucleus raphe interpositus 
The omnipause neurons are fusiform in shape and have horizontally 
oriented processes (open arrowheads). The two neurons shown contain 
neurofibrillary tangles. A: haematoxylin and eosin preparation, B: tau 
immunohistochemistry. Bar on B represents 5m 
 
Reproduced from Revesz et al. Brain 119:1137-43, 1996 with permission 
from Oxford University Press 
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6.2 Biochemical and genetic heterogeneity in typical and atypical PSP variants       
(paper 2)  
Morris et al.: Pathological, clinical and genetic heterogeneity in progressive 
supranuclear palsy. Brain 125:969-975, 2002[55] 
6.2.1 Background to research and questions arising   
In our study on the nucleus raphe interpositus (paper 1)[64] we could differentiate typical 
PSP from a PSP variant by morphometry employing stereological principles. In the second 
study, we investigated the hypothesis that the western blot profile of the PSP-tau and the 
distribution of the H1 and H2 tau (MAPT) gene haplotypes are different in typical PSP and 
the atypical PSP variants.  
 
6.2.2 Cases studied, methods and main findings of paper 2 
We investigated a cohort of 15 atypical and 11 typical PSP cases, which were available in the 
archives of the QSBB. Clinically typical cases met established diagnostic criteria including the 
presence of SGP[73]. The atypical group was heterogeneous; some cases presented with a 
Parkinson’s disease-type syndrome and in a minority of the atypical cases SGP was absent. 
There was no difference in the mean age of onset (P=0.9, Student’s t test) and mean age of 
death between the typical and atypical groups (P=0.09 Student’s t test) (Table 3). All cases 
were confirmed to have PSP neuropathological changes with additional Alzheimer’s disease-
type pathology in 19 of the 26 cases.  
 
For tau biochemistry insoluble tau was extracted from the frozen half of PSP brains using a 
previously  described method[28]. For genetic analysis DNA was extracted from frozen brain 
tissue samples and the tau haplotype analysis was carried out by using standard methods[5]. 
 
In both the typical and atypical cases the insoluble tau-enriched protein fraction was probed 
with SDS-PAGE (sodium dodecyl sulphate–polyacrylamide) gel electrophoresis and two anti-
tau antibodies, the phosphorylation independent TP70, recognising C-terminal amino acids 




The majority of the clinically typical cases (73%) showed the characteristic PSP-doublet 
electrophoretic migration pattern with two strong bands at 68kDa and 64kDa and a third 
weak band at 72kDa[21] (Figure 7, lanes 2,6-8) as compared with only one third (33%) of the 
atypical cases showing this pattern. The atypical PSP-tau western blot patterns included a 
triplet pattern with three strong bands at 68, 64kDa and 60kDa with a fourth weak band  
at 72kDa, as seen in Alzheimer’s disease (Figure 7, lane 3), and a pattern consisting of 6 to 8 
protein bands (Figure 7, lane 4), which migrated similarly to the 6 recombinant isoforms 
(Figure 7, lane 5).  
 
All cases, clinically classified as typical, were homozygous for the H1/H1 PSP susceptibility 
MAPT genotype compared with 73% of the atypical cases.  
  
 
Table 3   Comparison between clinically typical and atypical PSP  
PSP  n Mean age at 
onset (years) 






Atypical 11 66.3 76.3 73.3 33.3 
Typical 15 66 71.4 100 72.7 





1 2 3 4 5 6 7 8 
Figure 7    Western blots in typical and atypical progressive supranuclear palsy 
Electrophoretic migration patterns of insoluble tau probed with the TP70 (lanes 1-5) 
and PHF-1 (lanes 6-8) antibodies. Lane 1: PHF-tau triplet pattern in Alzheimer’s disease, 
lane 5: six recombinant tau isoforms. Typical PSP-tau doublet migration pattern: lanes 
2, 6-8; PHF-tau-like pattern lane 3; atypical pattern with 6 to 9 bands: lane 4. 







6.3 Conclusions of papers 1 and 2 
Using stereological tools for morphometry in our study reported in paper 1[64], we 
demonstrated for the first time that the omnipause neurons located in the nucleus raphe 
interpositus are severely affected by the PSP disease process. We demonstrated an ~50% 
loss of these neurons in typical PSP compared with normal controls and ~30% greater loss 
compared with the atypical cases. Furthermore, the observation of a greater NFT load in the 
typical cases was also consistent with the notion that the nucleus raphe interpositus is 
differentially affected in typical and atypical PSP with the atypical group being defined by the 
absence of SGP.  
 
In paper 2[55] we investigated whether typical and atypical PSP have different tau 
biochemical profiles and/or show differences in the distribution of the H1 and H2 MAPT gene 
haplotypes. We found that while the PSP genetic susceptibility tau gene haplotype and the 
characteristic, previously described PSP-tau doublet electrophoretic migration pattern were 
strongly associated with typical PSP, the atypical cases less frequently possessed MAPT 
H1/H1 genotype and often showed an atypical western blot pattern, which is consistent with 
an increased contribution of 3R-tau isoforms to PSP-tau in the atypical cases.   
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7. COMPARISON OF CLINICALLY WELL-CHARACTERISED ATYPICAL 
PSP WITH TYPICAL PSP (PAPERS 3 AND 4)  
7.1 The concept of Richardson’s syndrome (PSP-RS), PSP with parkinsonism  
(PSP-P) and PSP with pure akinesia with gait freezing (PSP-PAGF) 
Although early systematic investigations by our research group[55, 64] and also by 
others[52] raised the profile of atypical PSP, these studies, due to lack of satisfactory clinical 
definition of the atypical PSP variants, could not provide reliable neuropathological  criteria 
of atypical PSP[17]. This situation fundamentally changed when, using hierarchical cluster 
analysis, our research group could separate reliably three clinical phenotypes of PSP in a 
large cohort of neuropathologically confirmed and clinically well-documented cases 
(n=103)[77]. The largest group was represented by cases with classical clinical presentation, 
for which the term Richardson’s syndrome (PSP-RS) was introduced after J. Clifford 
Richardson, who first described the clinical signs and symptoms of PSP. The second group 
was represented by cases with a Parkinson’s disease-like presentation with asymmetry at 
disease onset, tremor and slight initial response to levodopa (PSP-parkinsonism or PSP-P). A 
third small group designated as PSP-pure akinesia with gait freezing (PSP-PAGF) was also 
identified[79]. PSP-RS patients were younger at both disease onset and death, had shorter 
disease duration than patients with PSP-P. PSP-RS patients were more frequently males than 
females while the sex distribution was even in PSP-P. Similar to our previous study described 
in paper 2,  biochemical investigation of PSP-tau showed a greater contribution by 3R-tau to 
the insoluble fraction of the tau protein in PSP-P than in PSP-RS while the effect of the H1/H1 
PSP susceptibility genotype was greater in PSP-RS than in PSP-P[77].  
 
7.2  Differences in tau-burden and its neuroanatomical distribution differentiate PSP-
RS and PSP-P (paper 3) 
Williams et al.: Pathological tau burden and distribution distinguishes progressive 
supranuclear palsy-parkinsonism from Richardson’s syndrome. Brain 130:1566-
1576, 2007[78] 
7.2.1  Background and research questions  
Although following the above described seminal study by Williams et al. 77] from the QSBB, 
the existence of PSP-P, and subsequently PSP-PAGF as clinical variants were independently 
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confirmed by other research groups[2, 17, 38, 58], the question remained unanswered 
whether the biological differences that may define these variants (i.e. a greater contribution 
by 3R-tau to PSP-tau in PSP-P, the greater effect of the H1/H1 PSP susceptibility genotype in 
PSP-RS and other unknown factors), also manifest in differences in the severity and/or the 
anatomical distribution of the tau pathology. Our study, published in paper 3[78] wished to 
answer these questions. 
 
7.2.2 Cases studied, methods and main findings of paper 3  
Forty two  pathologically proven cases (26 males, 16 females) (22 PSP-RS, 14 PSP-P, 6 PSP-
PAGF) were selected from the original cohort that was used for identifying the three clinical 
variants (see above)[77]. There was no difference in the prevalence of secondary pathologies 
(amyloid-A)plaques, cerebral amyloid angiopathy (CAA), argyrophilic grains, Lewy body 
pathology and cerebrovascular disease) between the groups. 
 
We used the AT8 anti-tau antibody, recognising pSer202/Thre205, for tau 
immunohistochemistry and an unbiased morphometric method for the quantitation of the 
different tau-positive lesions. Accordingly, the severity of NFT, Th, tufted astrocyte and CB 
pathologies was determined in 17 brain regions which are known to be affected by the PSP 
disease process. The continuous data were converted into a 5-tiered grading system (grades 
0 to 4) in each region; tau-positive Ths and CBs were pulled into a single measure (CB+Th).  
 
The ‘total tau-load’ ( of grades for all lesion types in all regions) was higher in PSP-RS than 
in PSP-P and PSP-PAGF (P=0.002) (Figure 8). The mean ‘regional tau-load’ determined in 17 
brain regions was, in general, also higher in PSP-RS than PSP-P or PSP-PAGF.   
 
As part of this project a simplified approach for the assessment of the tau pathology was also 
developed. It was found that when measures of CB+Th pathologies alone (omitting measures 
of NFTs and tufted astrocytes from the analysis) were graded semiquantitatively as 0 – 4 in 
three anatomical areas (substantia nigra, caudate and cerebellar dentate nucleus), these 
















Figure 8  ‘Total tau-load’ in typical (PSP-RS) and atypical progressive supranuclear palsy 
(PSP—P) 
The ‘total tau-load’ ( of grades for all lesion types in all areas) in PSP-RS is significantly 
greater than that in PSP-P, median (Mann-Whitney U test, P=0.002) and interquartile ranges 
(the small PSP-PAGF group was excluded from the analysis). PSP = progressive supranuclear 
palsy; PSP-RS = PSP-Richardson’s syndrome; PSP-P = PSP-parkinsonism.  
Reproduced from Williams et al. Brain 130:1566-76, 2007 with permission from Oxford 





























Figure 9   Correlation between PSP-tau scores and sum of all lesion grades 
(Spearman’s rho 0.93, P < 0.001) 
PSP = progressive supranuclear palsy 
Reproduced from Williams et al. Brain 130:1566-76, 2007 with permission 
from Oxford University Press  
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been determined by time-consuming assessment of the tau pathology in 17 brain regions. 
This simple semiquantitative measure was designated as ‘PSP-tau score’, which ranged 
between 0 to 12 (grades 0-4 in each of the 3 regions investigated) for each case. The 
usefulness of the ‘PSP-tau scores’ is shown by the excellent correlation between the ‘PSP-
tau scores’ and the previously determined ‘total tau load’ ( of grades for all lesion types in 
all 17 brain regions) (Figure 9).   
 
Using the ‘PSP-tau scores’ as surrogate markers of the severity of the cerebral tau-burden 
important and novel clinicopathological correlations were established; no PSP-P cases 
showed a ‘PSP-tau score’ higher than 5 (median 3) while the median for the PSP-RS group 
was 5, and that, similar to the ‘total tau-score’, the ‘PSP-tau scores’ could convincingly 
establish a difference in the tau-load between the PSP-RS and the PSP-P groups (Mann-
Whitney U test, P<0.001) (Figure 10, for comparison also see Figure 8).  
 
 Cases were also grouped using the ‘PSP-tau scores’ (PSP-tau score = 0-1; PSP-tau score = 2-
3; PSP-tau score = 4-5; PSP-tau score 6-7; PSP-tau score >7). Furthermore, median values of 
CB+Th determined previously by morphometry, for each of the 17 regions were calculated 
for each ‘PSP-tau score’ category (the relationship between the ‘PSP-tau scores’ and CB+Th 
median values is illustrated in Figure 11). This approach revealed that with the increase of 
the ‘PSP-tau scores’ there is a gradual topographical expansion and an increase in the 
severity of the tau pathology (Figure 11). In brief, the tau pathology initially is predominantly 
restricted to pallido-luyso-nigral structures with mild involvement of the premotor cortex 
with lower brainstem structures showing no or mild tau pathology (Figure 11B). In cases with 
higher PSP-tau scores the tau pathology gradually extends into the striatum, pontine nuclei, 
cerebellum (Figure 11C) and other cortical regions (Figure 11D). In cases with ‘PSP-tau 
scores’ 5-6 and >7, severe involvement of the subthalamic nucleus, substantia nigra, internal 
globus pallidus, neocortical areas, pontine nuclei and cerebellar structures is characteristic 









Figure 10   Using PSP-tau scores confirms a greater tau-load in PSP-RS than in PSP-
P  
PSP-tau scores according to clinical group, median (Mann-Whitney U test,                      P 
< 0.001), and interquartile ranges. PSP = progressive supranuclear palsy;                PSP-
RS = PSP-Richardson’s syndrome; PSP-P = PSP-parkinsonism.  
Reproduced from Williams et al. Brain 130:1566-76, 2007 with permission from 




Figure 11  Neuroanatomical distribution of the CB+Th (coiled body + thread) 
pathology (colour/grade) according to the PSP-tau scores  
Severity of CB+Th pathology:  pink = grade 1; purple = grade 2; red = grade 3; brown 
= grade 4. A = anatomical structures/control; B = PSP-tau score 0-1; C = PSP-tau 
scores 2-3; D = PSP-tau score = 4-5; E = PSP-tau score 6-7; F = PSP-tau score >7. No 
PSP-P case had a PSP-tau score higher than 5 illustrated by D. CB + Th pathology = 
coiled body + neuropil thread pathology; PSP = progressive supranuclear palsy.  
Reproduced from Williams et al. Brain 130:1566-76, 2007 with permission from 





7.3       PSP cases clinically presenting with corticobasal syndrome (PSP-CBS) is  
defined by a characteristic distribution of the tau pathology (paper 4) 
Ling et al.: Characteristics of progressive supranuclear palsy presenting with 
corticobasal syndrome: a cortical variant. Neuropathol Appl Neurobiol 40:149-163, 
2014[46] 
7.3.1  Background and research questions  
The term CBS is used to describe a characteristic set of clinical signs including apraxia in one 
hand, alien limb phenomenon, cortical sensory loss, dystonia and levodopa-unresponsive 
rigidity. Although initially it was described as the clinical manifestation of CBD, subsequently 
several other diseases, including PSP[6, 15, 50, 55, 74, 80] have been documented  as its 
cause.  
 
PSP-CBS, as a rare clinical PSP variant, emerged in the early 1990s[6, 15, 80]. Two previous 
studies investigated systematically 3 and 5 cases of this variant[6, 74] and concluded that 
PSP-CBS is associated with increased cortical tau pathology. However, neither of these two 
studies provided an insight into the overall distribution of the tau pathology in PSP-CBS, 
which we wished to address in the study, published in paper 4[46]. 
 
7.3.2 Cases studied, methods and main findings of paper 4 
227 neuropathologically confirmed PSP cases were archived in the QSBB between 1988 and 
2010, of which 9 had the clinical diagnosis of CBS/CBD (3.9% of all PSP cases). An additional 
case was obtained for our investigations through collaboration from the University of 
Nottingham, making our study the largest neuropathological investigation of this variant to 
date. 10 PSP-RS cases, matched for disease duration and age at death were used as controls. 
There was no difference in the mean age of onset, mean age at death and mean disease 
duration between the two groups (Table 4).  
 
Using tau immunohistochemistry with the AT8 antibody, the tau pathology (NFTs, PreTs, 
tufted astrocytes, Th, CBs) was quantitated in 15 brain regions. In each area, images were 
captured from 10 random microscopic fields, which were analysed by an image analysis 
software (Image-Pro; Media Cybernetics, Inc., Roper Industries, Rockville, USA). The 
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stereological tool, ‘areal fraction’ was used as a measure of tau-burden in each anatomical 
region. From the measurements in all 15 cerebral areas, the ‘total tau-load’ was calculated 
for each case; the tau-load in all the cerebral cortical areas provided the ‘cortical tau-load’ 
and in the basal ganglia the ‘basal ganglia tau-load’. After initial data analysis, NFTs, PreTs, 
tufted astrocytes, CBs were also quantitated in three anatomical regions (posterior frontal 
cortex, anterior frontal cortex and caudate nucleus), which were the regions that had been 
found to show robust differences in the tau-load between PSP-RS and PSP-CBS.  
 
Table 4   Demographic features of PSP-CBS and PSP-RS cases  
 PSP-CBS PSP-RS P values 
(Student’s t test) 
Mean age at disease onset 65.9 + 8.0 65.9 + 7.9 0.98 
Mean age at death 73.4 + 6.4 74.4 + 6.5 0.72 
Mean disease duration 7.5  + 2.7 8.6 + 4.4 0.51 
 
    
Using a four-tiered grading system neuronal cell loss was determined semiquantitatively in 
the substantia nigra and subthalamic nucleus.  
 
PSP-tau in PSP-CBS and in PSP-RS was studied by western blotting and MAPT gene H1 and 
H2 haplotypes were also determined.  
 
Pathological review confirmed that both the PSP-RS and PSP-CBD groups met established 
neuropathological diagnostic criteria of PSP[19, 30, 62]. There was no difference in neuronal 
cell loss in the subthalamic nucleus between the two groups (2 test, P > 0.05), but in the 
substantia nigra the neuronal cell loss was more severe in the PSP-RS group than in the PSP-
CBS cases (2 test, P = 0.018).  
 
Analysis of the median ‘regional’ tau-load showed that in the prefrontal (Mann-Whitney U 
test, P=0.003) and posterior frontal cortices (Mann-Whitney U test, P<0.001) and parietal 
subcortical white matter (Mann-Whitney U test, P=0.001) it was greater in PSP-CBS than in 
PSP-RS, while the median ‘regional’ tau-load in the caudate (Mann-Whitney U test, P<0.001) 
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and the subthalamic nucleus (Mann-Whitney U test, P<0.001) was greater in PSP-RS than in 
PSP- CBS (Figure 12).  It is of note that, although the ‘total tau-load’ ( of ‘regional tau-load’ 
in all 15 structures studied) was not different in the two disease groups (Mann-Whitney U 
test, P=0.176) (Figure 13A), the ‘cortical tau-load’ ( of ‘regional tau-load’ in all 7 cortical 
regions, studied) was significantly greater in PSP-CBS than in PSP-RS (Mann-Whitney U test, 
P<0.001) (Figure 13B). In contrast, the ‘basal ganglia tau-load’ ( of ‘regional tau-load’ in the 
caudate nucleus, putamen, globus pallidus and subthalamus) was significantly greater in PSP-
RS than in PSP-CBS (Mann-Whitney U test, P=0.003) (Figure 13C). Quantitation of the 
different tau lesion types confirmed that all lesion types were more frequent in the posterior 
frontal cortex in PSP-CBS than in PSP-RS (Mann-Whitney U test, P<0.001) while all tau-
positive lesion types were more frequent in the caudate nucleus in PSP-RS than in PSP-CBS 
(Mann-Whitney U test, P < 0.001).  
 
Protein analysis of PSP-tau by western blotting demonstrated the characteristic doublet 
pattern with two strong bands at 68kDa and 64kDa and a faster migrating band at ~33kDa as 
previously described[3, 75]. There was no difference in the distribution of the H1/H1 and 




Figure 12 The tau-load is greater in the posterior frontal (A) and prefrontal cortex (C) 
in PSP-CBS than in the corresponding areas in PSP-RS (B and D). In contrast, the tau-
load is greater in the caudate (F) and subthalamic nucleus (H) in PSP-RS than in PSP-
CBS (E and G).  
Tau immunohistochemistry (AT8 antibody). Bar on B represents 225 microns in all 
panels. PSP = progressive supranuclear palsy; PSP-CBS = PSP-corticobasal syndrome; 
PSP-RS = PSP-Richardson’s syndrome. 
Reproduced with permission from Ling et al. Neuropathol Appl Neurobiol 40:149-163, 
2014 under the terms of the Creative Commons Attribution License; Wiley’s Open 






Figure 13    ‘Total’, ‘cortical’ and ‘basal ganglia tau-load’ in PSP-CBS and PSP-RS 
The median ‘total tau-load’ is similar in PSP-CBS and PSP-RS (A). While the median 
‘cortical tau-load’ is significantly greater in PSP-CBS than in PSP-RS (B), the median ‘basal 
ganglia tau-load’ is significantly higher in PSP-RS than in PSP-CBS (C) (Mann-Whitney U-
test). This indicates a shift of the tau-burden from the basal ganglia to the cerebral 
cortices in PSP-CBS. PSP = progressive supranuclear palsy; PSP-CBS = PSP-corticobasal 
syndrome; PSP-RS = PSP-Richardson’s syndrome. 
Reproduced with permission from Ling et al. Neuropathol Appl Neurobiol 40:149-163, 
2014 under the terms of the Creative Commons Attribution License; Wiley’s Open Access 
Terms and Conditions. 
A B C 
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7.4    Conclusions of papers 3 and 4 
In the studies described in papers 3 and 4 we had the opportunity to investigate clinically 
well-characterised PSP variants, PSP-P, PSP-PAGF and PSP-CBS in comparison with PSP-RS. 
We showed that in each of the PSP variants the severity and distribution of the tau pathology 
deviates from those that can be found in the classical form of the disease (PSP-RS). In paper 
3[78], in which we determined the cerebral tau-load by analysing the tau pathology in 17 
brain regions in 42 cases, we could demonstrate that the tau-burden in the PSP-P and PSP-
PAGF variants is less severe and more restricted in its anatomical distribution than in PSP-RS. 
These findings have been validated by subsequent studies carried out by other research 
groups[17, 19, 38].  
 
The main finding of our paper 4[46] is that, although the total tau-burden is similar in PSP-
RS and PSP-CBS, there is a significant difference in the cortical and basal ganglia tau-load 
between these two PSP variants. This finding indicates a shift in the tau-burden from the 
basal ganglia to the cerebral cortex in PSP-CBS, which could be responsible for the clinical 
signs indicative of cortical dysfunction in this variant[6, 74]. Biochemical and genetic 
investigations of PSP-CBS, carried out in comparison with PSP-RS, demonstrated no 
difference in the PSP-tau electrophoretic migration pattern or the distribution of the H1 and 
H2 haplotypes between the PSP-CBS variant and the classical/typical form of the disease.  
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8.  PATTERNS OF DISEASE PROGRESSION IN CBD: LESSONS LEARNED 
FROM THE STUDY OF ‘INCIDENTAL’ (PRECLINICAL) CASES (paper 
5) 
Ling et al.: Astrogliopathy predominates the earliest stage of corticobasal 
degeneration pathology. Brain 139:3237-3252,2016[47] 
8.1.1 Background and research questions  
Previous studies have provided information about the neuropathological progression of 
tauopathies, including Alzheimer’s disease[8], Pick’s disease[37] and argyrophilic grain 
disease[66]. Such investigations identified, at least in Alzheimer’s disease and argyrophilic 
grain disease the anatomical areas that are first affected by the disease process. 
Furthermore, these studies also demonstrated that the specific tau pathologies, which 
characterise these conditions, affect with time, more and more cerebral areas and that 
progression stereotypically takes place in distinct hierarchical stages. However, patterns of 
progression of and, in particular, the structures first affected by tau pathology in PSP or CBD 
are not clearly understood and these questions in relation to CBD are addressed in paper 
5[47].  
 
8.1.2 Cases studied, methods and main findings 
With the help of a grant I received from the Karin & Sten Mortstedt CBD Solutions AB, 
Stockholm, Sweden and through collaboration with several UK, European and US brain 
banks, my research group had the opportunity to collect over 120 neuropathologically 
proven CBD cases, which is one of the largest case series which has been studied to date. 
This has allowed us to initiate a large-scale, still on-going study, which aims to decipher the 
enigma of disease progression, patterns of spread of the tau pathology and the 
neurobiological basis of disease variants in CBD. As part of this project, we investigated 4 
‘incidental’, clinically well-documented (preclinical) CBD cases, which provided data relevant 
for understanding where the disease process may start, and how the tau pathology may 
progress in the earliest disease stages. Three of the 4 cases have been reported in paper 
5[47]. In this study, we also included 6 end-stage cases (3 CBD-CBS and 3 CBD-RS) as controls 
(for demographic data, clinical diagnosis see Table 5).  
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‘Tau-load’ was determined in 20 brain regions whose involvement is characteristic during 
the CBD disease process. For this, the slides immunostained with the AT8 antibody, were 
digitised and ‘areal fractions’ (area occupied by tau-positive structures/total tissue area) 
were computed with the help of an image analysis software (Definiens Developer 2.3). In 
addition to determining the ‘regional tau-load’ in the 20 brain regions, the ‘total tau-load’ ( 
of all tau-positive lesions in all regions), the ‘cortical tau-load’ ( of all tau-positive lesions in 
all cortical regions) and the ‘basal ganglia tau-load’ ( of all tau-positive lesions in the caudate 
nucleus, putamen, globus pallidus, subthalamus) were also calculated. Furthermore, the 
severity of the tau-positive cellular pathology, including that of NFT, PreT, astrocytic plaque  
 
Table 5  Demographic data of preclinical and end-stage CBD cases 
Case No. Age at death 
(years) 
Disease duration  
(years) 
Clinical diagnosis 
Case 1 (preclinical) 63 N/A Tourette’s syndrome 
Case 2 (preclinical) 89 N/A US Ageing Project 
Case 3 (preclinical) 76 N/A Kidney transplant 
Case 4 (CBD-CBS) 78 8 CBS 
Case 5 (CBD-CBS) 72 5 CBS 
Case 6 (CBD-CBS) 73 7 CBS 
Case 7 (CBD-RS) 68 5 RS 
Case 8 (CBD-RS) 64 4 RS 
Case 9 (CBD-RS) 66 4 RS 
CBS = corticobasal syndrome; N/A = not applicable; RS = Richardson’s syndrome 
 
 and CB pathologies, was determined in the anterior/prefrontal and posterior frontal, 
parietal and temporal cortices and white matter, medial temporal lobe structures, basal 
ganglia, brainstem and cerebellar structures. The severity of the tau-positive thread 
pathology was determined semiquantitatively using a four-tiered grading system.   
 
Using a four-tiered grading system cell loss was also quantitated in the substantia nigra. The 
presence or absence of argyrophilic grains, Aß-positive plaque and Lewy body pathologies, 
CAA and cerebrovascular disease was documented.  
 47 
 
The MAPT gene (exons 10-13) was screened for mutations; the MAPT haplotypes were 
determined by H1/H2-tagging SNP rs1052553.  
 
Our data showed that the mean ‘regional tau-load’ in the group with ‘incidental’ CBD was 
less than that in the control end-stage cases with statistically significant difference identified 
in 16 selected regions (P<0.05). Both the ‘total tau-load’ (P=0.04) and the ‘basal ganglia tau-
load’ (P=0.001) was significantly less in the ‘incidental’ than in the control group with end-
stage CBD cases. A remarkable difference in the distribution of the tau pathology was noted 
in the frontal lobe; the tau deposition was characteristically severe in the posterior frontal 
region in the end-stage cases while this was far more prominent in the prefrontal cortical 
region than in the posterior frontal area in the ‘incidental’ cases (Figure 14). This was 
underlined by quantitative data, the mean anterior-to-posterior frontal tau-load ratio was 
16.04 in the ‘incidental’ CBD group and 1.36 in the end-stage CBD group. 
 
Quantitative analysis of cellular lesion types revealed important differences in that neuronal 
lesions were about four times more numerous than astrocytic plaques in the cortical regions 
(prefrontal, posterior frontal, parietal and temporal cortices) in the end-stage cases while 
the frequency of astrocytic plaques and neuronal lesions was similar in ‘incidental’ CBD 
(Figure 15) (mean neuronal to astrocytic plaque ratio was 4.20 in the end-stage and 0.91 in 
the preclinical cases (P < 0.001, 2 test)). 
 
The neuronal cell loss in the substantia nigra was graded as absent or mild in the ‘incidental’ 
CBD cases while this ranged from moderate to severe in the end-stage cases (P=0.03, 2 test).  
 
Tau-positive grains and mild cortical A pathology were observed in one ‘incidental’ case 
each.  
 
Analysis of exons 10-13 of the MAPT genes revealed no mutation; two cases had the H1/H1 




Case 1 Case 3 Case 6 
‘Incidental’ CBD End-stage CBD ‘Incidental’ CBD 
Figure 14   Tau pathology in the anterior and posterior frontal cortex in ‘incidental’ 
and end-stage CBD 
In the ‘incidental’ cases the tau pathology is more severe in the anterior than in the 
posterior frontal cortex while in end-stage CBD both the anterior frontal and posterior 
frontal regions show severe tau deposition. The astrocytic plaques are a predominant 
lesion type in ‘incidental’ CBD. Bar on L = 100µm. CBD = corticobasal degeneration. 







Figure 15  Frequency of neuronal lesions and astrocytic plaques in the cerebral cortex 
The neuronal lesions are ~four times greater than astrocytic plaques in end-stage CBD 
while these lesion types occur with equal frequency in incidental CBD (Error bars 
represent one standard error of the mean (SEM). CBD = corticobasal degeneration 
Reproduced from Ling et al. Brain 139:3237-3252, 2016 (supplementary material) with 





































8.1 Conclusions of paper 5 
The findings of this study showed that, compared with end-stage CBD cases, 1.) the tau 
pathology is significantly less severe in the ‘incidental’ (preclinical) CBD cases, and that 2.) 
astrocytic plaques are the predominant tau-positive cellular lesion type in ‘incidental’ CBD. 
Our data also indicate that 3.) the anatomical structures that are first affected by tau 
deposition in CBD are the basal ganglia and the prefrontal cortex with the posterior frontal 
cortex, which characteristically shows severe tau pathology in end-stage cases, being only 
mildly affected in the very early phases of the CBD disease process. 4.) In the ‘incidental’ 
cases the neuronal cell loss is absent or mild in the substantia nigra while this is moderate to 
severe in the end-stage cases.  
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9.  DISCUSSION OF THE SIGNIFICANCE OF THE FIVE STUDIES 
Since the mid-1990s a number of studies, including four of the five neuropathological studies 
discussed in this thesis, have been carried out in the QSBB, which have resulted in the 
establishment of the clinical diagnostic criteria of PSP variants such as PSP-P[77] and PSP-
PAGF[79] and, as a consequence, in a better understanding of the neuropathological basis of 
three of the PSP variants[46, 55, 64, 77-79]. The contribution of the QSBB to this area of 
research and, in particular, its role in the consolidation of the concept of atypical PSP, which 
by now includes several disease variants (Table 6), is widely acknowledged by researchers of 
other prestigious centres which are active in the field of PSP research[17].  
 
Table 6   Clinicopathological variants of progressive supranuclear palsy 
 Basal ganglia/brainstem 
predominant 
Cortical predominant  Cerebellar 









PSP = progressive supranuclear palsy; PSP-RS = PSP-Richardson’s syndrome; PSP-P = 
PSP-Parkinsonism; PSP-PAGF = PSP-pure akinesia with gait freezing; PSP-FTD = PSP-
frontotemporal dementia; PSP-PPA = PSP-primary progressive aphasia; PSP-AOS = 
PSP-apraxia of speech; PSP-C = PSP-cerebellar 
 
In the first study, reported in paper 1[64], we investigated the nucleus raphe interpositus as 
the omnipause neurons located in this nucleus had been shown to play an important role in 
the initiation of saccadic eye movements[12, 31, 32], which are affected in typical PSP, but 
not in some of the atypical PSP variants[15, 50]. In this study, in which we used stereology 
for morphometry, we could demonstrate for the first time that the nucleus raphe 
interpositus is severely affected by severe neuronal cell loss and NFT formation in PSP and 
that the involvement of this nucleus is significantly more severe in typical PSP than in atypical 
PSP defined by the absence of SGP. The significance of these findings is at least twofold: 1.) 
as the integrity of the omnipause neurons is a precondition of normal saccades[12, 31], 
findings of this study indicate that, in addition to degeneration of a number of other 
brainstem nuclei with a role in the organisation of saccadic eye movements[40, 53], 
depletion of and NFT formation in the glycinergic omnipause neurons contribute to the eye 
movement disorder in PSP and 2.) the PSP variant without SGP can be reliably differentiated 
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from typical PSP with SGP when appropriate quantitative neuropathological methods, based 
on stereological principles, are employed.  
  
The major aim of our second study (paper 2[55]) was to identify molecular markers that can 
help to differentiate atypical PSP from the classical form of the disease. In this study, we 
employed biochemical methods and extracted soluble and insoluble fractions of the tau 
protein from fresh frozen brain tissue, which we analysed with western blotting. Genetic 
testing for determining the H1 and H2 MAPT haplotypes was also performed. Our findings 
indicated that the H1/H1 PSP susceptibility genotype and the characteristic PSP-tau doublet 
electrophoretic migration pattern are prominently associated with typical PSP while the 
atypical cases, which clinically were more heterogeneous than those studied in paper 1, were 
less often associated with the H1/H1 genotype. Furthermore, the western blot patterns of 
PSP-tau indicated that in the atypical cases PSP-tau was often enriched in 3R-tau isoforms, 
which together with 4R-tau isoforms are found in the NFTs in  Alzheimer’s disease[25] (Figure 
4). A subsequent study from our brain bank, in which the clinical features of PSP-P were 
precisely defined, PSP-tau was also biochemically investigated in both PSP-P and PSP-RS 
cases[77]. This latter study together with that from the large US PSP Brain Bank at the Mayo 
Clinic[52] not only confirmed that insoluble tau is not exclusively composed of 4R-tau in PSP, 
but also that in atypical cases, co-existence of Alzheimer’s disease-type pathology and 
apolipoprotein E carrier status can influence the tau isoform composition of disease-
associated tau in PSP with atypical cases having increased amounts of 3R-tau.  
 
The greatest strength of our first two studies reported in paper 1 and paper 2 is that using 
appropriate neuropathological approaches and molecular markers, we could differentiate 
atypical PSP from typical PSP thus underpinning the concept that PSP is heterogeneous 
condition with several disease variants.  
 
Our third neuropathological study (reported in paper 3[78]) followed the investigation by 
Williams et al.[77] from the QSBB, which identified the clinical diagnostic criteria of the PSP-
P variant[77] in which disease duration is longer and parkinsonism dominates the early 
clinical picture. Furthermore, Williams et al. also firmly established that the most common 
pathology underlying PAGF is PSP[79]. In our follow-up neuropathological study, the findings 
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of which were published in paper 3[78], we used an unbiased approach for morphometry 
and performed an extensive quantitative analysis of the tau pathology in typical PSP (PSP-
RS), PSP-P and PSP-PAGF. We could demonstrate that there are major quantitative 
differences in the tau-burden between PSP-RS and the two atypical disease variants in that 
the deposition of the disease-associated, hyperphosphorylated tau is significantly more 
severe in PSP-RS than in PSP-P and PSP-PAGF. Furthermore, in both atypical variants the tau 
pathology is more restricted topographically than in PSP-RS. These findings 1.) contributed 
to the consolidation of the concept of PSP-P, which is now widely accepted as the most 
common atypical PSP variant[17, 19, 38] and they also indicate that 2.) there is a close 
association between clinical phenotype and the severity as well as topographical distribution 
of the tau pathology.  
 
In our fourth study (reported in paper 4)[46] we aimed to understand the neuropathological 
basis of the PSP-CBS variant. Using unbiased morphometry we could confirm findings of two 
previous studies[6, 74], which indicated that the cortical tau pathology is significantly 
increased in PSP-CBS. In addition, we could also demonstrate that, compared with typical 
PSP controls, the basal ganglia tau-load is significantly reduced in the PSP-CBS cases, which 
explains why the ‘total tau-load’ is not different in PSP-RS and PSP-CBS. It is of interest that 
a similar shift of the tau-load from the basal ganglia to the cerebral cortices has been 
documented in other cortical PSP variants, including PSP-frontotemporal dementia (PSP-
FTD)[7] and PSP-primary progressive aphasia (PSP-PPA)/PSP-apraxia of speech (PSP-
AOS)[39]. These observations and the findings reported in paper 3[78], strongly support the 
notion that, as in Alzheimer’s disease[8, 17], in PSP also there is a correlation between the 
severity as well as anatomical distribution of the tau pathology and the clinical phenotype.  
 
The initial major aims of our long-term, still on-going study on CBD were based on the 
hypothesis that after initiation of the CBD-specific tau pathology, it gradually spreads 
through established cerebral networks and, by the time disease process reaches the end-
stage phase, the tau pathology becomes severe and topographically extensive. Therefore, 
we wished to understand: 1.) where the tau pathology may start and 2.) which anatomical 
structures are affected by the tau pathology in the subsequent phases of disease progression 
in CBD. Analysis of three ‘incidental’ (clinically asymptomatic or preclinical) cases with CBD 
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pathology (paper 5[47]), which became available from the large archives of CBD cases stored 
in the QSBB and through collaboration with other UK, European and US centres, allowed us, 
at least in part, to answer these questions. We showed for the first time that: 1.) ‘incidental’ 
CBD cases have significantly less tau pathology than CBD cases with end-stage pathology, 
which were used as controls, 2.) compared with end-stage cases filamentous astrocytic tau 
inclusions (astrocytic plaques) are more prominent in ‘incidental’ CBD than in end-stage CBD 
cases and that 3.) while in the end-stage cases the posterior frontal cortex and parietal cortex 
are characteristically severely affected by tau deposition, in the ‘incidental’ cases the 
prefrontal  cortex was significantly more severely affected than the posterior frontal cortex 
and the parietal cortex, indicating that involvement of the prefrontal cortex precedes that of 
the posterior frontal cortex. Finally, 4.) the relatively greater tau burden in the prefrontal 
cortex and in the striatum as well as in the subthalamic nucleus in the ‘incidental’ cases, 
suggests that the striatal afferent connection to the dorsolateral prefrontal cortex and basal 
ganglia circuitry are likely to be the earliest neural network connections that are affected by 
the CBD-related tau pathology. The significance of the findings of our fifth study is shown by 
the scientific commentary that was commissioned by the Editor of Brain[41] and published 
together with paper 5 in the same issue of this journal. 
 
Since the publication of paper 5 in December 2016, we have had the opportunity to study a 
fourth ‘incidental’ CBD case, which became available for our ongoing research, courtesy of 
Professor James Ironside, National CJD Research and Surveillance Unit, Centre for Clinical 
Brain Sciences, University of Edinburgh (Revesz et al. unpublished observations). The 
significance of this recent observation is that in this case there is no cortical tau deposition 
and only the basal ganglia structures are affected by characteristic, CBD-specific tau 
pathology with a predominance of tau-positive astrocytic plaques. This observation has 
allowed us to outline more accurately the presumed initial steps of disease progression in 
CBD. Accordingly, 1.) the tau pathology first appears in basal ganglia structures, including the 
striatum and subthalamic nucleus 2.) whence it spreads to the dorsolateral prefrontal cortex 
via the striatal-frontal network followed by 3.) further spread of the tau pathology to the 
posterior frontal cortex using prefrontal-posterior frontal cortico-cortical neuroanatomical 
connections (Figure 16).  
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(The last paragraph including Figure 16 is unpublished material, which is included with 












Figure 16 Hypothesis of the anatomical spread of the tau pathology in the initial 
phases of corticobasal degeneration 
A: Striatal-prefrontal connections 
B: Prefrontal-posterior frontal connections  
Modified after Fig.14.17 in Nieuwenhuys, Voogd and van Huijzen: The Human 
Central Nervous System. Springer-Verlag, Berlin, 2008 
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10.    FUTURE RESEARCH QUESTIONS  
In the last decade, the hypothesis that disease-associated, amyloid-forming fibrillar proteins 
such as tau replicate important aspects of the behaviour of disease-associated prion protein 
(PrPSc) causing prion diseases, has gained considerable support. The notion that fibrillar, 
disease-associated tau has prion-like properties would indicate 1.) self-amplification of 
fibrillar tau via the process of ‘permissive templating’[29], 2.) cell-to-cell propagation of the 
aggregation process and that 3.) different tau conformers or ’strains’ are able to transmit 
unique, disease-specific or disease variant-specific pathological information, which could 
explain the clinicopathological differences that are observed in the different disease variants 
in both PSP and CBD[1, 13, 14, 24, 56, 71]. Although some experimental data already exist, 
which raise the possibility that conformationally distinct tau strains may be associated with 
PSP and CBD[67], future research will be required to show unequivocally that variants of PSP 
and CBD are also determined by distinct tau strains. One hopes that the continued grant 
support I have received from the Karin & Sten Mortstedt CBD Solutions AB, Sweden 
(http://www.cbdsolutions.se) since 2013 and extended in the end of 2017 for further two 
years, will enable my research group to pursue this line of research and answer some of 
these fundamentally important questions.   
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